Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey

International Journal of Infectious Diseases

Volumn 17, Issue 11, 2013, Pages e966-e970

  Demir, Tulin ^a   Buyukguclu, Tuncay ^b  

^a AHI EVRAN UNIVERSITY   (Turkey)

^b MINISTRY OF HEALTH   (Turkey)

Author keywords

Antimicrobial resistance; Fosfomycin tromethamine; Urinary tract infections

Indexed keywords

AMIKACIN; FOSFOMYCIN TROMETAMOL; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CITROBACTER; COMMUNICABLE DISEASE; CONTROLLED STUDY; DISK DIFFUSION; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HOSPITAL PATIENT; IN VITRO STUDY; KLEBSIELLA; MORGANELLA MORGANII; NONHUMAN; OUTPATIENT; PROTEUS; PSEUDOMONAS; SERRATIA; URINARY TRACT INFECTION;

ANTIMICROBIAL RESISTANCE; FOSFOMYCIN TROMETHAMINE; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FOSFOMYCIN; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; URINARY TRACT INFECTIONS;

EID: 84885377048     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.04.005     Document Type: Article

References (33)

1. Auer S., Wojna A., Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum beta-lactamase producing Escherichia coli. Antimicrob Agents Chemother 2010, 54:4006-4008.
2. Bano J., Alcala J.C., Cisneros J.M., Gril F., Oliver A., Horcajada J.P., et al. Community infections caused by extended-spectrum beta lactamase producing Escherichia coli. Arch Intern Med 2008, 168:1897-1902.
3. Chislett R.J., White G., Hills T., Turner D.P. Fosfomycin susceptibility among extended-spectrum beta-lactamase producing Escherichia coli in Nottingham, UK. J Antimicrob Chemother 2010, 65:1076-1077.
4. Knottnerus J., Nys S., Riet G., Donker G., Geerlings S.E., Stobberingh E. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?. J Antimicrob Chemother 2008, 62:356-359.
5. Oteo J., Bautista V., Lara N., Cuevas O., Arroyo M., Fernandez S., et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase producing Escherichia coli. J Antimicrob Chemother 2010, 65:2459-2463.
6. Schito G.C. Why fosfomycin trometamol as first line therapy for uncomplicated UTI?. Int J Antimicrob Agents 2003, 22:79-83.
7. Falagas M.E., Vouloumanou E.K., Togias A.G., Karadima M., Kapaskelis A.M., Rafailidis P.I., et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010, 65:1862-1877.
8. Patel S.S., Balfour J.A., Bryson H.M. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997, 53:637-656.
9. Lu C.L., Liu C., Huang Y., Liao C.H., Teng L.J., Turnidge J.D., et al. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother 2011, 55:4295-4301.
10. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECOSENS Project. J Antimicrob Chemother 2003, 51:69-76.
11. Marchese A., Gualco L., Debbia E.A., Schito G.C., Schito A.M. In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents 2003, 2:53-59.
12. Falagas M.E., Maraki S., Karageorgepoulos D.E., Kastoris A.C., Mavromanalakis E., Samonis G. Antimicrobial susceptibility of multidrug resistant (MDR) and extensively drug resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 2010, 35:240-243.
13. Pullukcu H., Tasbakan M., Sipahi O.R., Yamazhan T., Aydemir S., Ulusoy S. Fosfomycin in the treatment of extended-spectrum beta-lactamase producing Escherichia coli related lower urinary tract infections. Int J Antimicrob Agents 2007, 29:62-65.
14. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement M100-S21 2011, CLSI, Wayne, PA.
15. Bonfiglio G., Mattina R., Lanzafame A., Cammarata E., Tempera G. Fosfomycin tromethamine in uncomplicated urinary tract infections: a clinical study. Chemotherapy 2005, 51:162-166.
16. Matsumoto T., Muratani T., Nakahama C., Tomono K. Clinical effects of 2 days of treatment by fosfomycin calcium for acute uncomplicated cystitis in women. J Infect Chemother 2011, 17:80-86.
17. Alhambra A., Cuadros J.A., Cacho J., Gomez-Garces J.L., Alos J.I. In vitro susceptibility of recent antibiotic resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother 2004, 53:1090-1094.
18. Arslan H., Azap S.K., Ergönül Ö., Timurkaynak F. Risk factors for ciprofloxacin resistance among E. coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005, 56:914-918.
19. de Cueto M., Hernandez J.R., Lopez-Cerero L., Morillo C., Pascual A. Activity of fosfomycin against extended-spectrum beta-lactamase producing E. coli and K. pneumoniae. Enferm Infecc Microbiol Clin 2006, 24:613-616.
20. Farrell D.J., Morrissey I., De Rubeis D., Robbins M., Felmingham M. A UK multicenter study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect 2003, 46:94-100.
21. Liu H.Y., Lin H.C., Lin Y.C., Yu S.H., Wu W.H., Lee Y.J. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase producing E. coli and K. pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect 2011, 44:364-368.
22. Ko K.S., Suh J.Y., Peck K.R., Lee M.Y., Oh W.S., Kwon K.T., et al. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta lactamase producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis 2007, 58:111-115.
23. Falagas M.E., Kastoris A.C., Kapaskelis A.M., Karageorgepoulos D.E. Fosfomycin for the treatment of multidrug resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010, 10:43-50.
24. Hernandez M.S., Garcia J.A., Munoz J.L. In vitro activity of fosfomycin against ESBL-producing Enterobacteriaceae of urinary origin. Rev Esp Quimioter 2009, 22:25-29.
25. Biondo C.M., Rocha J.L., Tuon F.F. Fosfomycin in vitro resistance of E. coli from the community. Braz J Infect Dis 2011, 15:96.
26. Fuchs P.C., Barry A.L., Brown S.D. Fosfomycin tromethamine susceptibility of outpatient urine isolates of E. coli and E. faecalis from ten North American medical centers by three methods. J Antimicrob Chemother 1999, 43:137-140.
27. Wachino J., Yamane K., Suzuki S., Kimura K., Arakawa Y. Prevalence of fosfomycin resistance among CTX-M producing Escherichia coli clinical isolates in Japan and identification of novel plasmid mediated fosfomycin modifying enzymes. Antimicrob Agents Chemother 2010, 54:3061-3064.
28. Meier S., Weber R., Zbinden R., Ruef C., Hasse B. Extended-spectrum beta-lactamase producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection 2011, 39:333-340.
29. Ceran N., Mert D., Kocdogan F.Y., Erdem I., Adalati R., Ozyurek S., et al. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. J Infect Chemother 2010, 16:424-430.
30. Neuzillet Y., Naber K.G., Schito G., Gualco L., Botto H. Clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy. Med Mal Infect 2012, 42:66-75. French results of the ARESC study.
31. Alós J.I., García-Peña P., Tamayo J. Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections. Rev Esp Quimioter 2007, 20:211-215.
32. Garcia-Rodriguez J.A., Trujillano Martin I., Baquero F., Cisterna R., Gobernado M., Linares F., et al. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study. J Chemother 1997, 9:394-402.
33. Warren J.W., Abrutyn E., Hebel J.R., Johnson J.R., Schaeffer A.J., Stamm W.E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999, 29:745-758.